Xiujuan Hou

Xiujuan Hou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YLYuchen Liu
Yuchen Liu
HJHaixu Jiang
Haixu Jiang
TKTianlun Kang
Tianlun Kang
XSXiaojun Shi
Xiaojun Shi
XLXiaoping Liu
Xiaoping Liu
MLMeiling Li
Meiling Li
Background and aim: Rheumatoid arthritis (RA) is an autoinflammatory disease that may lead to severe disability. The diagnosis of RA is limited due to the need for biomarkers with both reliability and efficiency. Platelets are deeply involved in the pathogenesis of RA. Our study aims to identify the underlying mechanism and screening for related biomarkers.Methods: We obtained two microarray datasets (GSE93272 and GSE17755) from the GEO database. We performed Weighted correlation network analysis (WGCNA) to analyze the expression modules in differentially expressed genes identified from GSE93272. We used KEGG, GO and GSEA enrichment analysis to elucidate the platelets-relating signatures (PRS). We then used the LASSO algorithm to develop a diagnostic model. We then used GSE17755 as a validation cohort to assess the diagnostic performance by operating Receiver Operating Curve (ROC).Results: The application of WGCNA resulted in the identification of 11 distinct co-expression modules. Notably, Module 2 exhibited a prominent association with platelets among the differentially expressed genes (DEGs) analyzed. Furthermore, a predictive model consisting of six genes (MAPK3, ACTB, ACTG1, VAV2, PTPN6, and ACTN1) was constructed using LASSO coefficients. The resultant PRS model demonstrated excellent diagnostic accuracy in both cohorts, as evidenced by area under the curve (AUC) values of 0.801 and 0.979.Conclusion: We elucidated the PRSs occurred in the pathogenesis of RA and developed a diagnostic model with excellent diagnostic potential.

15 September 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
CZChen Zhang
Chen Zhang
SLSiyi Lu
Siyi Lu
TKTianlun Kang
Tianlun Kang
FMFanzhang Meng
Fanzhang Meng
TQTangliang Qian
Tangliang Qian
XHXiujuan Hou
Xiujuan Hou

7 June 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
MMMingwei Ma
Mingwei Ma
SLSiyi Lu
Siyi Lu
XHXiujuan Hou
Xiujuan Hou
CLChen Li
Chen Li

24 July 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
ASAlistair Lj Symonds
Alistair Lj Symonds
WZWei Zheng
Wei Zheng
TMTizong Miao
Tizong Miao
HWHaiyu Wang
Haiyu Wang
TWTieShang Wang
TieShang Wang
PWPing Wang
Ping Wang
The transcription factors Egr2 and 3 are essential for controlling inflammatory autoimmune responses of memory phenotype (MP) CD4 T cells. However, the mechanism is still unclear. We have now found that the Egr2+subset (PD-1highMP) of MP CD4 T cells expresses high levels of checkpoint molecules (PD-1 and Lag3) and also markers of effector T cells (CXCR3 and ICAM-1). Egr2/3 are not required for PD-1highMP CD4 cell development but mediate a unique transcriptional programme that effectively controls their inflammatory responses, while promoting homeostatic proliferation and adaptive responses. Egr2 negative PD-1highMP CD4 T cells are impaired in homeostatic proliferation and adaptive responses against viral infection but display inflammatory responses to innate stimulation such as IL-12. PD-1highMP CD4 T cells have recently been implicated in rheumatoid arthritis pathogenesis, and we have now found that Egr2 expression is reduced in PD-1highMP CD4 T cells from patients with active rheumatoid arthritis compared with healthy controls. These findings demonstrate that Egr2/3 control the inflammatory responses of PD-1highMP CD4 T cells and maintain their adaptive immune fitness.

22 February 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
CRChen Ru
Chen Ru
TQTangliang Qian
Tangliang Qian
XLXiaoping Liu
Xiaoping Liu
CWChaoxin Wang
Chaoxin Wang
WLWeizhong Li
Weizhong Li
CLChen Li
Chen Li

1 October 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
CZChen Zhang
Chen Zhang
TKTianlun Kang
Tianlun Kang
TQTangliang Qian
Tangliang Qian
MMMingwei Ma
Mingwei Ma
XHXiujuan Hou
Xiujuan Hou
CLChen Li
Chen Li
Secukinumab, a monoclonal antibody targeting interleukin-17 (IL-17), has exhibited encouraging results in the therapeutic management of palmoplantar pustulosis (PPP). The development of alopecia areata (AA) is closely related to IL-17, and IL-17A inhibitors were considered as a potential treatment modality. Therefore, the development of AA during secukinumab treatment for PPP is a rare adverse event that has been rarely reported worldwide. Here we report a 35-year-old female patient with PPP who developed AA after completing the induction period of secukinumab treatment. Discontinuing secukinumab and initiating treatment with tofacitinib resulted in a significant improvement in both PPP and AA. The emergence of AA in this patient can be attributed to paradoxical skin reactions associated with IL-17 inhibitors. Tofacitinib appears to alleviate biologic-induced AA during PPP syndrome treatment.